Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2007-09-25 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Full Year Statutory Accounts 44 pages ?Kb
Regulatory Filings
2007-09-25 English
Expanded Vaccine Development Program 2 pages ?Kb
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement from Imugene Limited dated 25 September 2007. It discusses the development of new vaccines in the company's product pipeline, including poultry and pig vaccines. The content focuses on product development updates and pipeline expansion rather than financial results, regulatory filings, or shareholder information. The document is relatively short (3876 characters) and reads like a corporate announcement about product development progress. It does not contain financial statements, voting results, management changes, or legal proceedings. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to updates on the company's product development pipeline, which is a form of capital/asset development relevant to investors and financing activities.
2007-09-24 English
Appendix 4E-Preliminary Final Report Year End 30 June 2007 9 pages ?Kb
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final report Year ended 30 June 2007' and contains detailed financial statements including income statement, balance sheet, cash flow statement, notes to the financial statements, and commentary on results for the fiscal year ended 30 June 2007. It explicitly states that the report is based on accounts that are in the process of being audited. The content includes comprehensive financial data and analysis for a full fiscal year, which aligns with the characteristics of an Annual Report. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are essentially annual reports or preliminary annual financial statements. The document is lengthy (15,000 characters) and contains substantive financial information, not just an announcement or certification. Therefore, the appropriate classification is Annual Report (10-K). FY 2007
2007-08-29 English
Fourth quarter activities and cashflow reports 8 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Imugene Quarterly Update' and covers the period from 1 April 2007 to 30 June 2007, indicating it is a quarterly report. It includes detailed operational highlights, trial results, patent progress, and financial information such as cash flow statements and cash balances. The presence of an Appendix 4C Quarterly report, which is a regulatory form used in Australian markets for quarterly reporting, further confirms this. The document contains substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2007
2007-07-30 English
PRRS Vaccine Trial Commences in the US 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 18 July 2007 about the commencement of a vaccine trial by Imugene. It discusses the start of a clinical trial for a pig PRRS vaccine in the US, providing background on the disease, the vaccine technology, and the company's business focus. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management changes, no merger or acquisition information, and no earnings or interim report data. The document is a company announcement about a product development milestone, typical of a general regulatory announcement. It is relatively short (3251 characters) and does not contain detailed financial or operational data that would classify it as a report or presentation. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2007-07-17 English
FINSIA Healthcare Forum Presentation 14 pages ?Kb
Regulatory Filings
2007-06-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.